Recursion Pharmaceuticals, Inc. (Recursion) announced the completion of its Phase 2 clinical trial for REC-994, a treatment for Cerebral Cavernous Malformation (CCM), with the primary endpoint of safety and tolerability met. The trial also showed encouraging trends in MRI-based exploratory efficacy measures. Recursion plans to present the data at a medical conference and submit for publication. Additionally, Recursion has entered into an agreement with Exscientia to combine efforts in bringing better medicines to patients more rapidly and cost-efficiently. The proposed transaction will see Exscientia shareholders receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts over the next 18 months. The transaction is subject to approval by both companies' shareholders and is expected to close by early 2025.

Recursion Pharmaceuticals, Inc. (Recursion) announced the completion of its Phase 2 clinical trial for REC-994, a treatment for Cerebral Cavernous Malformation (CCM), with the primary endpoint of safety and tolerability met. The trial also showed encouraging trends in MRI-based exploratory efficacy measures. Recursion plans to present the data at a medical conference and submit for publication. Additionally, Recursion has entered into an agreement with Exscientia to combine efforts in bringing better medicines to patients more rapidly and cost-efficiently. The proposed transaction will see Exscientia shareholders receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share. The combined company is expected to have a diverse portfolio of clinical and near-clinical programs, with approximately 10 clinical readouts over the next 18 months. The transaction is subject to approval by both companies' shareholders and is expected to close by early 2025.